CG Oncology (NASDAQ:CGON) Price Target Cut to $79.00 by Analysts at Royal Bank Of Canada

CG Oncology (NASDAQ:CGON) had its price target reduced by Royal Bank Of Canada from $81.00 to $79.00 in a research note released on Friday,Benzinga reports. They currently have an outperform rating on the stock.

A number of other research firms also recently weighed in on CGON. JPMorgan Chase & Co. increased their price target on CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of CG Oncology in a research note on Wednesday, July 29th. Wolfe Research started coverage on CG Oncology in a report on Tuesday, May 19th. They issued a “peer perform” rating for the company. Wedbush increased their target price on CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a report on Friday, July 17th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $83.18.

CG Oncology Price Performance

CGON opened at $75.10 on Friday. The firm has a 50 day simple moving average of $67.12 and a 200 day simple moving average of $63.95. CG Oncology has a fifty-two week low of $23.65 and a fifty-two week high of $77.00. The company has a market cap of $6.62 billion, a price-to-earnings ratio of -27.92 and a beta of 0.23.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.24). CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 26.58%. The business had revenue of $1.16 million during the quarter, compared to the consensus estimate of $0.36 million. As a group, analysts expect that CG Oncology will post -2.89 EPS for the current year.

Insider Buying and Selling at CG Oncology

In other CG Oncology news, Director Brian Guan-Chyun Liu purchased 371,085 shares of the stock in a transaction on Thursday, June 25th. The stock was bought at an average cost of $66.87 per share, for a total transaction of $24,814,453.95. Following the completion of the acquisition, the director directly owned 1,886,236 shares of the company’s stock, valued at $126,132,601.32. The trade was a 24.49% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James Mulay sold 24,165 shares of the stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $75.16, for a total value of $1,816,241.40. Following the completion of the sale, the director owned 24,165 shares of the company’s stock, valued at $1,816,241.40. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 37,129 shares of company stock valued at $2,663,817. Company insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On CG Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Whittier Trust Co. of Nevada Inc. bought a new stake in CG Oncology in the 4th quarter valued at $27,000. NFSG Corp bought a new position in CG Oncology during the 1st quarter worth about $34,000. Comerica Bank increased its holdings in CG Oncology by 100.4% during the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after purchasing an additional 515 shares in the last quarter. Fifth Third Bancorp acquired a new stake in shares of CG Oncology in the 1st quarter valued at about $74,000. Finally, KBC Group NV acquired a new stake in shares of CG Oncology in the 1st quarter valued at about $78,000. 26.56% of the stock is currently owned by institutional investors and hedge funds.

Key CG Oncology News

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $82 to $85 and assigned an “overweight” rating, implying approximately 13.2% upside. Benzinga
• Positive Sentiment: Truist Financial also raised its target from $82 to $85 and upgraded its view to “buy,” citing a more constructive outlook for CG Oncology. The Fly
• Positive Sentiment: HC Wainwright maintained a “buy” rating and a $100 target. The firm modestly increased its long-term FY2030 EPS forecast to $6.88 from $6.77, reinforcing expectations for significant future earnings growth as the company advances its pipeline. MarketBeat
• Positive Sentiment: CG Oncology reported second-quarter revenue of $1.16 million, substantially above the $0.36 million consensus estimate, while also highlighting pipeline and business progress. CG Oncology Second-Quarter Results
• Neutral Sentiment: Royal Bank of Canada lowered its target from $81 to $79 but retained an “outperform” rating. The reduced target still represents roughly 5.2% potential upside and may reflect valuation calibration rather than a fundamental downgrade. Ticker Report
• Negative Sentiment: CG Oncology reported a quarterly loss of $0.90 per share, wider than the $0.66 consensus loss and the $0.54 loss recorded a year earlier. The earnings shortfall could limit gains despite strong analyst targets. Zacks Q2 Earnings Report
• Negative Sentiment: HC Wainwright reduced its FY2029 EPS estimate from $2.43 to $2.34, signaling some moderation in its intermediate-term earnings outlook, although its buy rating and $100 target remain unchanged.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.